0. DOCID:18366 SCORE: 0.00568037031479712
DOCNO: 2270173
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: secondary
QUALIFIER: secondary
AUTHOR: K Böszörményi K
AUTHOR: E Kanitz E
AFFILIATION: Országos Korányi Tbc és Pulmonológiai Intézet, Budapest, II. Belosztály.
PUBTYPE: Journal Article
JOURNALTITLE: Orvosi hetilap.
COUNTRY: HUNGARY
TITLE: [Clinical course and prognosis of pleuro-pulmonary metastases in patients after surgery for breast cancer]
PUBDATE: 19901201
The data of 63 female patients suffering from pulmonary and/or pleural metastases of breast cancer are recorded. The patients received chemotherapy, according to the CMF (Cyclosphosphamide-Methotrexate-Fluorouracil) scheme, and in case of appropriate indication, a hormone-therapy as well. The mean survival time of the deceased was 22 months whereas the mean follow-up time of those still living is 61 months. These results are better, than those of the literature, mainly if they are compared to the data of patients with inoperable primary lung cancer.

1. DOCID:21647 SCORE: 0.00489399988755516
DOCNO: 10134440
AUTHOR: A Tabarrok A
AFFILIATION: Economics Department, George Mason University, Fairfax, VA 22030.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Journal of health economics.
COUNTRY: NETHERLANDS
TITLE: Genetic testing: an economic and contractarian analysis.
PUBDATE: 19940301
Medical researchers are rapidly identifying the genetic causes of many diseases. Genes that increase the risk of contracting Alzheimer's, colon and breast cancer, Huntington's, cystic fibrosis and numerous other diseases have been identified. Genetic tests can reveal an individual's probable health status many years in advance of sickness. Many fear that this will lead to 'genetic discrimination' in the employment and health insurance markets. Solutions such as consent laws are impractical and create adverse selection problems. A new form of insurance, genetic insurance, can eliminate these problems and allow everyone to be insured.

2. DOCID:28513 SCORE: 0.00465299325011277
DOCNO: 12585984
AUTHOR: Marsha Wittink M
AUTHOR: Joseph B Straton JB
AFFILIATION: Department of Family Practice and Community Medicine, University of Pennsylvania, Philadelphia, USA.
PUBTYPE: Comment
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of family practice.
COUNTRY: United States
TITLE: Self-examination does not reduce breast cancer mortality.
PUBDATE: 20030201
Breast self-examination does not decrease breast cancer mortality, according to the results of this randomized controlled trial of 266,000 women who were given intensive instruction in breast self-examination. These findings correspond with the US Preventive Services Task Force policy not to recommend breast self-examination for the reduction of breast cancer mortality.

3. DOCID:21970 SCORE: 0.00445906770708051
DOCNO: 8168066
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Diagnosis, Computer-Assisted
QUALIFIER: diagnosis
QUALIFIER: pathology
AUTHOR: I Zavrazhina I
AUTHOR: L P Yaroslavsky LP
AFFILIATION: NCI, National Institutes of Health, Bethesda, MD 20892.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer letters.
COUNTRY: IRELAND
TITLE: Computer-assisted technologies in lung cancer diagnosis and staging.
PUBDATE: 19940301
A paradigm for digital image processing in radiological diagnosis and an appropriate algorithmic instrumentation toolset for the implementation of image processing methods on inexpensive computers and workstations are outlined briefly. Examples of computer-assisted technologies for lung cancer differential diagnosis are given that exhibit considerable increase in diagnostic accuracy. Multimodal image processing and data fusion in lung cancer diagnosis are discussed and a 'road map' for examining lung cancer patients is suggested on the basis of clinical experience in the use of different modalities for lung cancer staging.

4. DOCID:23660 SCORE: 0.0040092419653998
DOCNO: 7658781
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Chromosomes, Human, Pair 13
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: S Thorlacius S
AUTHOR: L Tryggvadottir L
AUTHOR: G H Olafsdottir GH
AUTHOR: J G Jonasson JG
AUTHOR: H M Ogmundsdottir HM
AUTHOR: H Tulinius H
AUTHOR: J E Eyfjord JE
AFFILIATION: Molecular and Cell Biology Research Laboratory, Reykjavik, Iceland.
PUBTYPE: Journal Article
JOURNALTITLE: Lancet.
COUNTRY: ENGLAND
TITLE: Linkage to BRCA2 region in hereditary male breast cancer.
PUBDATE: 19950801
Breast cancer is rare in men, and family history of the disease is a risk factor. The recently discovered BRCA2 gene on chromosome 13q is thought to account for some families with increased risk of breast cancer, including male breast cancer. We describe a family with multiple cases of male breast cancer but, interestingly, no increase in female breast cancer. Linkage to the BRCA2 region is demonstrated and all the affected men share the same haplotype for the BCRA2 markers and loss of the other alleles in their tumours.

5. DOCID:22788 SCORE: 0.00398877033794323
DOCNO: 9030238
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Antineoplastic Agents
DESCRIPTOR: Clinical Trials, Phase I
AUTHOR: M Shimoyama M
AFFILIATION: Nagoya National Hospital.
PUBTYPE: Journal Article
JOURNALTITLE: Gan to kagaku ryoho. Cancer & chemotherapy.
COUNTRY: JAPAN
TITLE: [Introduction of anticancer agents to phase I clinical trials]
PUBDATE: 19970101
Because about half of patients with cancer could not be cured by the present standard therapy, new effective anticancer agents should be developed and introduced at the clinical level. However, there are several important and specific issues from scientific, medical, statistical, and ethical viewpoints in the design and conducting of phase I clinical trials of new anticancer agents. Clinical safety data management is critically important in phase I clinical trials. Phase I clinical trials are vastly different from phase II or III clinical trials in terms of these issues. This paper discusses issues of early anticancer drug development to be solved or improved.

6. DOCID:26616 SCORE: 0.00384287024713037
DOCNO: 9858290
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnostic use
QUALIFIER: radionuclide imaging
QUALIFIER: diagnostic use
QUALIFIER: diagnostic use
QUALIFIER: methods
QUALIFIER: methods
AUTHOR: R Burt R
AFFILIATION: Department of Radiology, VAMC and Indiana University, Indianapolis 46202, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Clinical nuclear medicine.
COUNTRY: UNITED STATES
TITLE: Dual isotope F-18 FDG and Tc-99m RBC imaging for lung cancer.
PUBDATE: 19981201
PURPOSE: To produce fluorodeoxyglucose (FDG) images with markers for normal organs and large blood vessels in patients with suspected lung cancer. METHODS: Dual isotope SPECT images were made using F-18 FDG- and Tc-99m-labeled autologous red cells. RESULTS: FDG-positive lesions are localized in relation to major structures when they are viewed in a fused rotating three-dimensional display or in cross sections. CONCLUSIONS: Tc-99m red cell and FDG fusion imaging provides relative location information for lung tumors.

7. DOCID:17791 SCORE: 0.00382306197531093
DOCNO: 8240734
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Immunotherapy
QUALIFIER: therapy
AUTHOR: P B Chapman PB
AUTHOR: A N Houghton AN
AFFILIATION: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in immunology.
COUNTRY: ENGLAND
TITLE: Non-antibody immunotherapy of cancer.
PUBDATE: 19931001
Immunotherapeutic agents have become important additions to the list of anti-cancer treatments; further progress will require more information about how the immune system can respond to tumor cells. Tumor cells can avoid eliciting an immune response through several mechanisms. Understanding these mechanisms may suggest strategies to manipulate tumor cells so that they trigger an effective immune response. Another strategy being developed is to improve the therapeutic index of cytokines so that better anti-tumor effects can be elicited with less toxicity.

8. DOCID:25770 SCORE: 0.00376960591400527
DOCNO: 9922817
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Extracorporeal Membrane Oxygenation
DESCRIPTOR: Pneumonectomy
DESCRIPTOR: Postoperative Complications
QUALIFIER: surgery
QUALIFIER: surgery
QUALIFIER: therapy
AUTHOR: H Verhelst H
AUTHOR: J Vranken J
AUTHOR: F Muysoms F
AUTHOR: L Rondelez L
AUTHOR: H Schroë H
AUTHOR: R De Jongh R
AFFILIATION: Department of Thoracovascular Surgery, Ziekenhuis Oost-Limburg, Genk, Belgium.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Acta chirurgica Belgica.
COUNTRY: BELGIUM
TITLE: The use of extracorporeal membrane oxygenation in postpneumonectomy pulmonary oedema.
PUBDATE: 19981201
A 59-year-old male developed a severe adult respiratory distress syndrome following a right pneumonectomy for pulmonary cancer. Extracorporeal membrane oxygenation for 11 days was life-saving. The operation was considered curative, but the patient died nine months later with multiple metastases. The pathogenesis and treatment for postpneumonectomy pulmonary oedema and an explanation for rapid dissemination of the cancer are stated.

9. DOCID:23065 SCORE: 0.00376659991188183
DOCNO: 8695763
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Rearrangement
QUALIFIER: genetics
AUTHOR: D Sheer D
AUTHOR: J Squire J
AFFILIATION: Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX, UK.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in cancer biology.
COUNTRY: UNITED STATES
TITLE: Clinical applications of genetic rearrangements in cancer.
PUBDATE: 19960201
Genetic aberrations in cancer cells can be of immediate relevance to the patient. They enable definitive diagnoses to be reached and sub-classification of certain tumour types into good or bad prognostic groups, information which can influence therapy. These aberrations can also be used as tumour markers for monitoring the response to therapy. Major technological advances in the last few years have facilitated these applications in the routine clinical setting and encouraged searches for new genetic markers. As the genes directly affected are identified and their roles in tumorigenesis elucidated, they are likely to provide novel targets for therapeutic intervention.

10. DOCID:21026 SCORE: 0.00369266818461279
DOCNO: 9046828
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: isolation & purification
QUALIFIER: virology
AUTHOR: S Akiba S
AUTHOR: M Tokunaga M
AUTHOR: C Fujiyama C
AFFILIATION: Kagoshima University, Faculty of Medicine.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [EBV-related stomach cancer and HLA]
PUBDATE: 19970201
Recently, the involvement of EB virus in gastric cancer has drawn world-wide attention. In Japan, it is suspected that EB-virus is related to 5-10% of stomach cancer. In this paper, we briefly reviewed EBV-related immune responses and HLA distributions in EBV-related diseases. A brief description on our recent studies on the comparison of HLA distributions in EB-virus positive and negative stomach cancers was also given.

11. DOCID:26246 SCORE: 0.00365047209715153
DOCNO: 10575902
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Isoflavones
QUALIFIER: prevention & control
QUALIFIER: administration & dosage
QUALIFIER: prevention & control
AUTHOR: L M Chiechi LM
AUTHOR: A Lobascio A
AUTHOR: A Grillo A
AUTHOR: T Valerio T
AFFILIATION: Clinica Ostetrica e Ginecologica III, Università degli Studi, Bari. m.chiechi@pangeanet.it
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Minerva ginecologica.
COUNTRY: ITALY
TITLE: [Phytoestrogen-containing food and prevention of postmenopausal osteoporosis and cardiovascular diseases]
PUBDATE: 19990901
Food phytestrogens and prevention of postmenopausal osteoporotic and cardiovascular disease. Phytestrogens are diphenolic compounds, widely found in plants and foods, with structural and biological estrogen-like similarities. Their anti-estrogenic effects are well known and studied due to the possibility to prevent some tumors such as breast and prostate cancer. In menopause they have an estrogenic-like action on lipidic and bone metabolism. Phytestrogens rich foods can positively affect the postmenopausal osteoporotic and cardiovascular pathology.

12. DOCID:21953 SCORE: 0.00361521211743812
DOCNO: 7566929
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: S Eckhardt S
AFFILIATION: Országos Onkológiai Intézet, Budapest.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Orvosi hetilap.
COUNTRY: HUNGARY
TITLE: [Use of taxol in the management of malignant tumors]
PUBDATE: 19950901
Taxol is a novel cytostatic agent which inhibits the depolymerisation of microtubulin. The stabilization of this important substance leads to cellular arrest and consecutively apoptosis. Accordingly, taxol is capable to influence neoplastic growth in several malignancies. At present the following standard regimen is recommended: 175 mg/m2 taxol in a 3-hour i. v. infusion following corticosteroid + diphenhydramine + cimetidine premedication. Its antitumour activity has been proved especially in advanced ovarian and breast cancer. Encouraging results have been reported in various bronchial, testicular malignancies, lymphomas and leukemias. Clinical investigations in several other malignancies are ongoing.

13. DOCID:22354 SCORE: 0.0036019135088954
DOCNO: 9095461
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Bioethics
DESCRIPTOR: Genetic Enhancement
DESCRIPTOR: Morals
DESCRIPTOR: Quality of Life
QUALIFIER: standards
AUTHOR: J M Torres JM
AFFILIATION: Departamento de Humanidades, Universidad Nacional del Sur, Bahla Blanca, Argentina.
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of medicine and philosophy.
COUNTRY: NETHERLANDS
TITLE: On the limits of enhancement in human gene transfer: drawing the line.
PUBDATE: 19970201
Enhancement-line human genetic engineering has recurrently been targeted for bioethical discussion and is usually (if not always) illustrated by examples alluding to a genetic technology that is far beyond our current possibilities. By discussing an ambitious project related to solid tumor cancers--multidrug resistance (MDR)--the present paper places the question on a more realistic plane and draws bioethical conclusions to serve as guidelines in the field. The paper also establishes the inadequacy of the prevalent concept of genetic medicine as one of substitution.

14. DOCID:17739 SCORE: 0.00352730833430206
DOCNO: 1908721
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: immunology
QUALIFIER: immunology
AUTHOR: A I Autenshlius AI
AUTHOR: V A Semernikov VA
AUTHOR: S V Khutornoĭ SV
AUTHOR: O B Sadovskaia OB
AUTHOR: E A Mikhaĭlova EA
PUBTYPE: Journal Article
JOURNALTITLE: Biulleten' eksperimental'noĭ biologii i meditsiny.
COUNTRY: USSR
TITLE: [Determination of antibodies to cross-reacting antigens of microorganisms in oncological diseases]
PUBDATE: 19910501
It was studied antibodies to saprophytic microorganism Bacillus megaterium H glycoprotein in healthy, oncological, non-oncological gastrointestinal patients and animals. High level of antibodies to microbial glycoprotein in blood sera was revealed in cancer and precancer patients. Analogical results were obtained in mice A/Sn and Balb/c with inductive or transplanted tumors. It has been suggested the use of Bacillus megaterium H glycoprotein (M. m. 65-70 kD) for immunological monitoring.